By Gilang Cahya 
Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have demonstrated a significant breakthrough in tackling non-responsive lung tumours through a novel combination of therapeutic agents. Their findings, published today in the esteemed journal Nature Communications, reveal that simultaneously targeting tumours through multiple pathways can dramatically enhance the efficacy of immunotherapies, potentially offering new hope for patients with lung cancer.
A Multi-pronged Attack on Tumour Resistance
The groundbreaking study utilized a sophisticated approach in mouse models of lung cancer, combining a newly identified inhibitor of the KRAS G12C mutation with a compound designed to block the SHP2 protein. This dual inhibition strategy was then augmented by an immune checkpoint inhibitor, a class of drugs that has revolutionized cancer treatment by releasing the brakes on the immune system, allowing it to recognize and attack cancer cells.
The KRAS gene is a critical player in cell growth and division. Mutations in KRAS, particularly the G12C variant, are prevalent in a significant percentage of lung cancers, especially non-small cell lung cancer (NSCLC), and have historically been considered challenging to target directly. SHP2, a protein tyrosine phosphatase, plays a complex role in cancer signaling pathways, often promoting tumour growth and survival, and can also influence the tumour microenvironment in ways that suppress immune responses. Immune checkpoint inhibitors, such as those targeting PD-1 or CTLA-4, work by preventing cancer cells from evading immune surveillance, a common mechanism of resistance.
The synergy observed in this research lies in the sequential and complementary actions of these agents. The KRAS G12C inhibitor directly attacks the mutated cancer cells, while the SHP2 inhibitor further disrupts tumour growth and, crucially, appears to recalibrate the tumour microenvironment. This recalibration is thought to make the tumour more susceptible to immune attack. The subsequent introduction of the immune checkpoint inhibitor then unleashes the body’s own immune system to more effectively eliminate the weakened cancer cells.
Tumour Eradication and Enhanced Immune Memory
In mice with functional immune systems, the "triplet combination" therapy proved remarkably effective. Tumours not only shrank significantly but, in a notable proportion of cases, were completely eradicated. Furthermore, these mice demonstrated a heightened resistance to the recurrence of lung cancer, suggesting that the treatment may induce a more robust and durable anti-tumour immune memory. This long-term protection is a crucial aspect of cancer therapy, aiming to prevent relapse after initial treatment success.
Breaking Down the "Immune Cold" Barrier
Perhaps one of the most significant implications of this research is its potential to overcome a major hurdle in cancer immunotherapy: "immune cold" tumours. These tumours are characterized by a lack of immune cell infiltration and a generally unresponsive microenvironment, rendering them largely impervious to conventional immunotherapies. The study demonstrated that even in these recalcitrant cases, the combination therapy succeeded in sensitizing the tumours to immune checkpoint inhibitors. This suggests that the combined approach can effectively "warm up" these immune-cold tumours, making them visible and vulnerable to the immune system.
Dr. Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick and co-senior author of the study, highlighted the significance of these findings. "Blocking genes like KRAS in lung cancer has led to some exciting new developments, but we still see problems with resistance," Dr. Downward stated. "We’ve now been able to report partial or complete eradication of tumours in mice by combining KRAS and SHP2 inhibitors with immunotherapy. We also showed that this combination therapy allows ‘immune cold’ tumours to respond to the body’s own defences."
The Dawn of a New Era in Cancer Treatment?
The success observed in preclinical mouse models provides a compelling rationale for advancing this combination therapy into human clinical trials. If similar efficacy and safety profiles are observed in patients, it could represent a paradigm shift in the treatment of lung cancer, particularly for those who have not responded to existing therapies or who have developed resistance.
The researchers believe that the targeted compounds create a critical "window of opportunity." This window allows the immune checkpoint inhibitor to effectively engage the immune system, enabling the body’s natural defences to mount a decisive attack against the tumour. This intricate interplay between targeted molecular therapies and the immune system underscores the evolving sophistication of cancer treatment strategies.
Panos Anastasiou, a PhD student in the Oncogene Biology Laboratory at the Crick and the study’s first author, emphasized the broader implications of the research. "Our work stresses the importance of targeting tumours from all angles, especially ones that don’t respond easily to treatment," Anastasiou commented. "It will be critical to see if the combination of inhibitors works in the same way in humans."
A Collaborative Endeavor and Future Directions
This research was a testament to extensive collaboration within the Crick Institute, with contributions from teams specializing in Experimental Histopathology, Bioinformatics and Biostatistics, Genomics, Scientific Computing, Flow Cytometry, Cell Services, and Biological Resources. The project was primarily funded through a collaborative research agreement with Revolution Medicines, a company focused on developing novel targeted therapies for cancer. Additional financial support was provided by the European Union and the Wellcome Trust, underscoring the international importance and recognition of this scientific endeavor.
The path forward involves rigorous clinical evaluation. The next crucial step will be to assess the safety and efficacy of this combination therapy in human patients with lung cancer. This will likely involve carefully designed clinical trials, starting with Phase I studies to determine optimal dosing and identify potential side effects. Understanding and mitigating any adverse events associated with combining multiple potent therapeutic agents will be paramount to ensuring patient safety and maximizing treatment benefit.
Beyond clinical translation, further research will be necessary to fully elucidate the precise mechanisms by which the SHP2 inhibitor primes tumours for immunotherapy and to identify biomarkers that could predict which patients are most likely to benefit from this approach. Such advancements could pave the way for personalized treatment strategies, ensuring that the right patients receive the most effective therapies.
Context and Background: The Evolving Landscape of Lung Cancer Treatment
Lung cancer remains a leading cause of cancer-related deaths worldwide. For decades, treatment options were limited, primarily involving surgery, chemotherapy, and radiation. The advent of targeted therapies and immunotherapies has dramatically changed the landscape, offering new hope and significantly improving survival rates for many patients.
Targeted therapies, like KRAS inhibitors, aim to block specific molecular pathways that drive cancer growth. Immunotherapies, such as immune checkpoint inhibitors, harness the power of the patient’s own immune system to fight cancer. However, a significant challenge has been the development of resistance to these therapies, leading to disease progression.
The KRAS G12C mutation, specifically, has been a particularly stubborn target. While the development of KRAS G12C inhibitors represented a major scientific achievement, not all patients respond, and resistance often emerges. Similarly, while immune checkpoint inhibitors have been transformative, a substantial proportion of patients do not benefit from them, often due to the presence of immune-cold tumours.
This research by the Crick Institute and Revolution Medicines addresses these critical unmet needs. By combining agents that target different aspects of cancer biology and immune evasion, they are exploring a more comprehensive strategy to overcome resistance and improve outcomes. The potential to make "immune cold" tumours responsive to immunotherapy is particularly exciting, as it could broaden the applicability of this powerful treatment modality to a larger patient population.
The timeline of this research likely spans several years, from initial hypothesis generation and laboratory experiments to compound development, preclinical testing in animal models, and finally, the publication of these significant findings. The rigorous scientific process involved in such studies underscores the commitment to evidence-based medicine and the slow but steady progression of scientific discovery.
The implications of this research extend beyond lung cancer. The principles of combining targeted therapies with immunotherapies to overcome resistance and modulate the tumour microenvironment are broadly applicable to many other cancer types. As our understanding of cancer biology and immunology deepens, such multi-faceted treatment strategies are expected to become increasingly central to cancer care.
While caution is always warranted when translating preclinical findings to human patients, the robust results observed in this study offer a compelling reason for optimism. The journey from laboratory discovery to widespread clinical application is complex and demanding, but breakthroughs like this represent vital steps forward in the ongoing battle against cancer. The collaborative spirit between academic institutions and biotechnology companies, as exemplified by this partnership, is crucial for accelerating the pace of innovation and bringing life-saving treatments to those who need them most.
